ONA Navigation Summit 2016
Sugar and Cancer: Mitigating the Affects of Diet on Cancer
April 26, 2016Food speaks to our genes; its message or signal can turn the immune system on or off. Consumption of a high carbohydrate or sugar diet can increase risk of cancer.
Navigator-specific Interventions and Multidisciplinary Care Team Collaboration Improves Care and Outcomes for Patients with GI Cancers
April 25, 2016The GI ONN is a relatively new position whose role is not only to remove barriers to care, but also to facilitate timely, comprehensive, and evidence-based care for patients with GI cancers.
The Community Health Needs Assessment: Building the Backbone of a Navigation Process
April 13, 2016A navigation process that effectively addresses a community's health care disparities and barriers to cancer care is driven by a triennial Community Health Needs Assessment (CHNA).
The Role of Physical Therapy in the Continuum of Cancer Care
April 13, 2016Oncology rehabilitation is cost-effective; it lowers both direct and indirect health care costs and improves physical and psychological quality of life for patients with cancer.
Navigating the Older Patient Through Cancer Care
April 11, 2016A working knowledge of frailty, multimorbidity, and geriatric syndromes, as well as self-awareness of and sensitivity to ageism are key skills for oncology navigators caring for older patients.
Understanding Mental Issues in Patients With Cancer and Caregivers
April 11, 2016Navigators need to be aware of the signs and symptoms of cognitive and emotional distress and be able to determine which patients and family members need to be managed more closely.
Getting Started: Implementation of an Oncology Navigation Program That Meets Community Needs
April 08, 2016Patient navigation ensures patients with cancer achieve diagnostic resolution in a timely manner, leading to optimal outcomes for both patients and the community.
Beyond Treatment: Anticipating the Late Effects of Cancer Treatment in Survivors
April 08, 2016Side effects are defined as long-term or late. Although the 2 types are difficult to distinguish, their distinction is both clear and important.
Sign Up for Free e-newsletters
ONA Articles
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- Handling Chemotherapy Premedications
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |